Recent Updates
Recently added Catalysts
TAK Positive Sentiment

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study

Friday, October 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Takeda reported positive results from the Phase 3 G-HOPE-001 study of TAK-921 in advanced gastric cancer. The study demonstrated statistically significant improvements in overall survival and progression-free survival for patients with CLDN18.2-positive tumors. These findings were presented at a major medical conference, highlighting the drug's potential efficacy.

Market Sentiment Analysis

POSITIVE FACTORS

  • Statistically significant improvements in overall survival.
  • Clinically meaningful results in progression-free survival.
  • Positive outcomes from Phase 3 G-HOPE-001 study.
  • Presented at the European Society for Medical Oncology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+27%
120-day peak, hindsight
Typical move
1.5%
average across 15 past catalysts
Lead asset
NDI-034858 study drug
NDA/BLA · Moderate to Severe Plaque Psoriasis

Full Press Release Details

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical On

Frequently Asked Questions

What is TAK-921?

TAK-921, also known as arcotatug tavatecan, is a drug for advanced gastric cancer.

What were the results of the G-HOPE-001 study?

The study showed statistically significant improvements in overall and progression-free survival.

Who presented the study results?

Takeda presented the results at the European Society for Medical Oncology.

What type of cancer was studied?

The study focused on advanced gastric or gastroesophageal junction adenocarcinoma.

ShareAdd on Google
Tags: TAK Takeda TAK-921 advanced gastric cancer overall survival progression-free survival
Last updated: Oct 23, 2026

Biotech snapshot

Lead asset
NDI-034858 study drugNDA/BLA
Moderate to Severe Plaque Psoriasis →

Catalyst track record

+27%
best trade around TAK's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for TAK.

See every catalyst's timing & PoA →